^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    4d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Nov 2036 --> Dec 2031 | Trial primary completion date: Nov 2036 --> Dec 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    4d
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (clinicaltrials.gov)
    P1, N=694, Recruiting, AbbVie | N=512 --> 694 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment change • Trial primary completion date • Adverse events • First-in-human
    |
    PD-1 (Programmed cell death 1)
    |
    BRAF V600E • BRAF V600 • HER-2 mutation
    |
    Avastin (bevacizumab) • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    7d
    Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer. (PubMed, Clin Cancer Res)
    Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.
    Clinical • P1 data • Journal • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET expression
    |
    telisotuzumab adizutecan (ABBV-400)
    14d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Not yet recruiting, AbbVie
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    14d
    A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2 trial
    15d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Dec 2031 --> Nov 2036 | Trial primary completion date: Dec 2031 --> Nov 2036
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    22d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR expression • MET expression
    1m
    Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=105, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Chong Kun Dang Pharmaceutical
    New P1/2 trial • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression
    1m
    Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. (PubMed, CPT Pharmacometrics Syst Pharmacol)
    Unconjugated MMAE payload exposures were correlated with a greater probability of grade ≥ 3 treatment-emergent adverse events. The 1.9 mg/kg Q2W dose maximized efficacy while balancing adverse events in patients with c-Met overexpressing NSCLC.
    PK/PD data • Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET overexpression • MET expression
    |
    Emrelis (telisotuzumab vedotin-tllv)
    2ms
    M25-287: A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (2024-518586-10-00)
    P2/3, N=44, Recruiting, AbbVie Deutschland GmbH & Co. KG
    New P2/3 trial • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    Tagrisso (osimertinib) • telisotuzumab adizutecan (ABBV-400)
    2ms
    M24-064: A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants with Refractory Metastatic Colorectal Cancer expressing c-Met Protein Level Above Cutoff (2024-512804-20-00)
    P2/3, N=87, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P2/3 trial • Adverse events
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • telisotuzumab adizutecan (ABBV-400)